Geode Capital Management LLC Has $2.68 Million Stock Holdings in Personalis, Inc. (NASDAQ:PSNL)

Geode Capital Management LLC increased its holdings in shares of Personalis, Inc. (NASDAQ:PSNL) by 20.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 498,470 shares of the company’s stock after purchasing an additional 83,068 shares during the period. Geode Capital Management LLC’s holdings in Personalis were worth $2,683,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Barclays PLC grew its position in shares of Personalis by 45.4% during the 3rd quarter. Barclays PLC now owns 65,468 shares of the company’s stock worth $352,000 after buying an additional 20,444 shares during the period. Jane Street Group LLC boosted its stake in Personalis by 154.3% during the third quarter. Jane Street Group LLC now owns 164,281 shares of the company’s stock worth $884,000 after acquiring an additional 99,671 shares in the last quarter. State Street Corp grew its holdings in Personalis by 34.5% in the third quarter. State Street Corp now owns 175,142 shares of the company’s stock worth $942,000 after purchasing an additional 44,900 shares during the period. Centiva Capital LP bought a new stake in Personalis in the third quarter valued at $380,000. Finally, Walleye Capital LLC acquired a new position in shares of Personalis during the third quarter valued at about $897,000. 61.91% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on PSNL shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $7.25 target price on shares of Personalis in a research report on Friday, December 20th. HC Wainwright upped their target price on Personalis from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Friday, December 20th.

Personalis Price Performance

PSNL opened at $5.98 on Wednesday. The firm has a market capitalization of $422.48 million, a PE ratio of -3.56 and a beta of 1.75. Personalis, Inc. has a fifty-two week low of $1.12 and a fifty-two week high of $7.20. The company’s 50-day moving average is $4.68 and its 200 day moving average is $4.31.

Personalis (NASDAQ:PSNL) last posted its earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.31). Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The company had revenue of $25.71 million during the quarter, compared to the consensus estimate of $20.67 million. During the same quarter in the prior year, the business earned ($0.51) EPS. As a group, analysts expect that Personalis, Inc. will post -1.41 EPS for the current year.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.